LXRX
NASDAQLexicon Pharmaceuticals Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$1.90-0.02 (-1.30%)
01:30 PM07:45 PM
News · 26 weeks78-37%
2025-12-072026-05-31
Mix3090d
- Insider15(50%)
- Other7(23%)
- SEC Filings6(20%)
- Earnings2(7%)
Latest news
25 items- INSIDERDirector Swain Judith L converted options into 89,312 shares, increasing direct ownership by 105% to 174,486 units (SEC Form 4)4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)
- INSIDERDirector Sullivan Diane E. converted options into 89,312 shares, increasing direct ownership by 243% to 126,122 units (SEC Form 4)4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)
- INSIDERDirector Sobecki Christopher J converted options into 89,312 shares, increasing direct ownership by 44% to 293,177 units (SEC Form 4)4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)
- INSIDERDirector Cheung Ivan converted options into 89,312 shares (SEC Form 4)4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)
- INSIDERDirector Amouyal Philippe converted options into 89,312 shares, increasing direct ownership by 31% to 374,486 units (SEC Form 4)4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)
- INSIDERDirector Barker Sam L converted options into 89,312 shares, increasing direct ownership by 72% to 213,771 units (SEC Form 4)4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)
- INSIDERDirector Debbane Raymond converted options into 89,312 shares, increasing direct ownership by 5% to 1,995,498 units (SEC Form 4)4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)
- PRLexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific SessionsTHE WOODLANDS, Texas, June 03, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that it will present data from clinical studies of sotagliflozin in Type 1 diabetes (T1D) and pilavapadin in diabetic peripheral neuropathic pain (DPNP) at the American Diabetes Association (ADA) 2026 Scientific Sessions, being held June 5-8 in New Orleans, Louisiana. "We look forward to engaging with the diabetes community at ADA 2026, as well as sharing additional data from clinical studies of our novel, orally administered investigational therapies for T1D and DPNP," said Craig Granowitz, M.D., Ph.D., Lexicon's senior vice president and chief medical officer. "In particul
- PRLexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare ConferenceTHE WOODLANDS, Texas, May 28, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that Company management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 4, 2026 at 2:00 p.m. ET in New York City. The live event and a replay of the presentation can be accessed via the Events page of the Company's website at https://investors.lexpharma.com/. About Lexicon Pharmaceuticals Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients' lives. Lexicon has a pipeline of drug candidates in discovery, preclinical, and clinical development in neuropathic pain, hypertrophic car
- PRLexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor ConferenceTHE WOODLANDS, Texas, May 12, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that Company management will participate in a fireside chat at the 4th Annual H.C. Wainwright BioConnect Investor Conference, taking place at the Nasdaq World Headquarters in New York City, on May 19, 2026. The live event and a replay of the presentation can be accessed via the Events page of the Company's website at https://investors.lexpharma.com/. About Lexicon Pharmaceuticals Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients' lives. Lexicon has a pipeline of drug candidates in discovery, preclinical, and clinical deve
- INSIDERDirector Artal Participations S.A R.L. converted options into 20,421,735 shares (SEC Form 4)4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)
- SECSEC Form 10-Q filed by Lexicon Pharmaceuticals Inc.10-Q - LEXICON PHARMACEUTICALS, INC. (0001062822) (Filer)
- SECLexicon Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - LEXICON PHARMACEUTICALS, INC. (0001062822) (Filer)
- PRLexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical UpdatesSONATA-HCM anticipated to be fully enrolled mid-2026 Resubmission of NDA for ZYNQUISTA® in type 1 diabetes anticipated mid-2026 with potential for approval this year Clinical development of LX9851 initiated by Novo Nordisk Capital raise, development milestone payments, and recent $100 million loan facility reinforce strong financial position Conference call and webcast at 8:30 am ET THE WOODLANDS, Texas, May 07, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), today reported financial results for the three months ended March 31, 2026, and provided an update on key corporate milestones and accomplishments. "We have been intently focused on progressing our la
- SECLexicon Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits8-K - LEXICON PHARMACEUTICALS, INC. (0001062822) (Filer)
- INSIDERSEC Form 4 filed by Director Amouyal Philippe4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)
- INSIDERSEC Form 4 filed by Director Sobecki Christopher J4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)
- INSIDERSEC Form 4 filed by Director Barker Sam L4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)
- INSIDERSEC Form 4 filed by Director Cheung Ivan4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)
- INSIDERSEC Form 4 filed by Director Swain Judith L4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)
- INSIDERSEC Form 4 filed by Director Sullivan Diane E.4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)
- INSIDERSEC Form 4 filed by Director Debbane Raymond4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)
- PRLexicon Pharmaceuticals Announces $100 Million Loan Facility with Hercules CapitalTHE WOODLANDS, Texas, May 04, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) announced today that it has entered into a loan facility with Hercules Capital, Inc. (NYSE:HTGC) that provides up to $100 million in borrowing capacity. Access to this non-dilutive capital provides Lexicon with greater financial flexibility through both an extended interest-only period and maturity date and the opportunity to further strengthen its balance sheet to support pivotal upcoming regulatory and commercial milestones. "Operational excellence, financial discipline and financial flexibility are key pillars of our corporate strategy for long-term growth," said Scott Coiante, Lexicon's
- SECLexicon Pharmaceuticals Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - LEXICON PHARMACEUTICALS, INC. (0001062822) (Filer)
- PRLexicon Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026THE WOODLANDS, Texas, April 30, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced the Company will release its first quarter 2026 financial results on Thursday, May 7, 2026, prior to market open. Management will conduct a conference call and live webcast at 8:30 a.m. ET (7:30 a.m. CT) that day to discuss the financial results and to provide a business update. Participants can access the conference call live via webcast on the Events page of the Company's website at https://investors.lexpharma.com/. Participants who wish to ask a question may join by phone at 800-715-9871 and use passcode 9826247. An archived version of the webcast will be available on t
LXRX FAQ
6 questionsWhat does Lexicon Pharmaceuticals Inc. do?
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; LX9211, which is in Phase II clinical development for the treatment of neuropathic pain; and LX2761. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was...Where does LXRX stock trade?
Lexicon Pharmaceuticals Inc. (LXRX) is listed on NASDAQ.What sector and industry is LXRX in?
Lexicon Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about LXRX?
Lexicon Pharmaceuticals Inc. has had 5 recent analyst actions on file. The most recent action was from Leerink Partners: Market Perform with a $100.00 price target on 2025-03-05.What companies are similar to LXRX?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare LXRX side-by-side with any of them on Quantisnow.How can I track LXRX on Quantisnow?
Quantisnow aggregates Lexicon Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow LXRX to receive live email and push alerts on every new disclosure.